anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The effect of crocina on the production of IL-4, IL-1β, IL-17, IL-10 and TGF-β by ELISA assay;The effect of crocina on gene expression of transcription factors T-bet, GATA3, FOXP3, ROR-γt by Real-Time PCR; The effect of crocina on number of helper T cells type one and two, regulatory T cells and T helper type 17 cells by Flow Cytometry analysis; The effect of crocina on the reduction of pain and joint inflammation by WOMAC osteoarthritis index, vas score pain and CRP, ESR diagnostic tests . Design: Randomized, Double-blind and Placebo controlled; Study population: Patients with Osteoarthritis; Volume: 40 persons; Method: Osteoarthritis patients will be divided into two groups according to age and sex; Crocina tablets will be prescribed to the first group a tablet 15 mg daily along with the conventional medicines. 30 pills of crocina or placebo in cans quite similar and be encoded with Excel Software will be given to the patients completely random; The distributor and the patient will have no knowledge of the contents of the cans; After the end of each month, the patients will receive similar to their previous code. Blood sampling of patients will be done before drug administering and four months after the treatment. Major Inclusion Criteria: Osteoarthritis patients with age 40 to 75 years; The severity of joint damage between grade 2 and 3; Patients without history of injury; Patients with the Body Mass Index (BMI) less than 30. Major Exclusion Criteria: Osteoarthritis patients with age less than 40 and more than 75; The severity of joint damage in the grade one and four; Patients with history of injury and body mass index 30 or more. Intervention: Treatment with prescription of drug at dose of 15 mg daily crocin in the study group and placebo in the control group; Time: 4 months. Main Outcome Measures: Osteoarthritis, Pain, Inflammation, Crocin, IL-4, IL-1 beta, IL-17, IL-10, TGF-beta, Cell surface CD127, The expression of T-bet; GATA3; FOXP3; RORgt and the number of Th1, Th2, T-regulatory and Th17
The present invention discloses a traditional Chinese drug preparation for treating gilles tourette syndrome. The traditional Chinese drug preparation comprises the following raw drugs, wherein the raw drugs comprise, by weight, 30-50 parts of tall gastrodia rhizome, 30-50 parts of medlar, 30-50 parts of pilose asiabell root, 20-40 parts of bezoar, 20-40 parts of thinleaf milkwort root, 20-40 parts of white peony root, 10-30 parts of tangerine peel, 10-30 parts of oyster, 10-20 parts of incised notopterygium rhizome and root and 10-20 parts of licorice root. The traditional Chinese drug preparation provided by the present invention is provided for treating the gilles tourette syndrome. During treating the gilles tourette syndrome, the traditional Chinese drug preparation is added to boiled water, and taken for twice a day; the dose is 5-10 g per each time; a treatment course comprises five days; the gilles tourette syndrome can be cured after usually 2-3 treatment courses. The traditional Chinese drug preparation provided by the present invention is adopted in the clinic for a plurality of years, the results show that: 102 cases of patients are treated, and 76 cases of the patients are cured. The traditional Chinese drug preparation provided by the present invention has advantages of significant treatment effect, low recurrence rate, no toxic and side-effect, less adverse reaction and the like.
Apparatus and methods for mobile monitoring of drainage catheters are provided. The device may be configured to perform operations to present a user interface. The user interface may be configured to provide an output interface configured to prompt a user to input catheter usage information, the catheter usage information being information related to draining fluid from a patient using the catheter. The user interface may be configured to provide an input interface to a user to input catheter usage information. The device may also be configured to receive catheter usage information input by the user through the user interface. The device may also be configured to generate catheter management information based on the received catheter usage information. A method for mobile monitoring of a drainage catheter may include using a processor to perform steps that a device is configured to perform.
The invention relates to an antioxidant selenium-doped graphene nano dot drug, and a preparation method and application thereof, and relates to the technical field of drug preparation. Solves the technical problems of poor treatment effect and large side effect in MI antioxidation treatment in the prior art. The antioxidant selenium-doped graphene nano dot drug is selenium-doped graphene nano dots modified with phenylselenophene on flaky graphene, and the expression of the selenium-doped graphene nano dot drug is Se NPs. The antioxidant selenium-doped graphene nanodot medicine is prepared by taking phenylselenophene and polyethylene glycol as raw materials. The invention also provides application of the antioxidant selenium-doped graphene nanodot medicament in preparing medicaments for treating acute myocardial infarction. The antioxidant selenium-doped graphene nanodot drug can effectively target and enrich ischemic myocardial parts to play a therapeutic role on the premise of ensuring the stability of the drug in a complex ischemic myocardial environment, and meanwhile, the systemic distribution is avoided to ensure the safety.
PROBLEM TO BE SOLVED: To obtain food product and beverage which contains an antioxidant substance extracted from cacao beans with ethanol, has excellent preventing action on diabetic complications with high safety and can reduce the load on patient due to diabetes in the dietary therapy and the movement therapy. SOLUTION: This food product or beverage contains an antioxidant substance extracted from cacao beans with ethanol, preferably in an amount of 0.2-10wt.%. The antioxidant substance is extracted by dipping 100 pts.wt. of cacao beans in 400-700 pts.wt. of an ethanol aqueous solution containing ethanol at a weight ratio of water to ethanol of 30/70 to 0/100 at room temperature to - 50 deg.C under stirring for 16-24 hours. Ethanol is evaporated from the extract under reduced pressure and the residue is freeze-dried to give the objective substance in a powder form. It is preferred that a daily dose is 10-500mg/kg body weight.
The invention relates to a cyclophilin-propyl-valyl-isoleucyl-leucinide (Trp-Ala-Val-Ile-Leu cyclopeptide) with hepatoma cytotoxicity and alpha-glucosidase inhibitory activity and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. The cyclic-propyl-valyl-isoleucyl-leucinide is fifteen-membered cyclic pentapeptide formed by connecting tryptophan, alanine, valine, isoleucine and leucine through an amide bond. This is a novel compound and has not been reported in the literature. The compound can be obtained by culturing frog-feces mould, and then extracting and separating. The pure product of the ring color-propyl-valyl-isoleucyl-leucinyl peptide is white powder, and the half inhibition concentration (IC  50 ) of the pure product on liver cancer cells HepG2 is as follows: 54.19 μg/mL, half inhibitory concentration of α -glucosidase (IC  50 ) was: 63.64. Mu.g/mL. The compound can be used as potential medicine for treating liver cancer and slimming medicine.
Studies have proven that there is 100% blockade of the phrenic nerve with the in-plane approach to the interscalene brachial plexus block. The patient population with pulmonary comorbidities with poor reserve cannot afford to have a further deterioration of their pulmonary status due to phrenic nerve blockade. These patients are not ideal candidates for increased opiate therapy for intraoperative and post-surgical pain as well due to further depression of their respiratory function. To optimize their pain control as well as avoid any respiratory-related morbidity and mortality, it is ideal to develop a technique which can provide appropriate brachial plexus block at the interscalene level while completely avoiding any local anesthetic spread to the phrenic nerve.

The study aims to examine the influence of out of plane interscalene approach to a brachial plexus block on the effect of phrenic nerve blockade. Practitioner preference and institutional norms often influence the in plane approach for the above-mentioned block. The most common practice at our institution is the in plane approach to the brachial plexus block.
The participants will be subjected application of the laying on of hands by the passistas who will give the Spiritist "passe". Patients remain in the supine bed blindfolded for 5 minutes, around 8 weeks.
The chemical composition of Ganoderma lucidum ethanol extracts was systematically analyzed and identified by ultra-high performance liquid chromatography-quadrupole electrostatic field orbitrap high-resolution mass spectrometry(UPLC-Orbitrap-HRMS). The fragmentation pattern of the representative chemical compounds was summarized, and the potential anti-liver fibrosis active compounds of G. lucidum acting on the farnesoid X receptor(FXR) target were studied to elucidate its pharmacodynamic substance basis. Preliminarily, 95 chemical constituents of G. lucidum ethanol extracts were identified, including 24 ganoderic acids, 9 ganoderenic acids, 13 lucidenic acids, 3 ganolucidic acids, 1 ganoderma lactone, 40 other triterpenoids, 4 fatty acids, and 1 other constituent. In addition, the fragmentation patterns of the representative compounds were also analyzed. The structural characteristics of ganoderic acids and ganoderenic acids were the C30 skeleton, containing free-COOH and-OH groups, which could easily lose H_2O and CO_2 to form fragment ions. The D-ring was mostly a five-membered ring, which was prone to breakage. Lucidenic acids were the lanosterolane-type of the C27 skeleton, and the side-chain structure became shorter and contained the same free-COOH and-OH compared with ganoderic acids, which had been reduced from 8 to 5 cartons and prone to lose H_2O and CO_2. Then, six reported FXR receptor agonists were selected to form a training set for establishing a pharmacophore model based on FXR ligands. The 95 identified chemical constituents of G. lucidum were matched with the pharmacophore, and the optimal pharmacophore model 02(sensitivity=0.750 00, specificity=0.555 56, ROC=0.750) was selected for the virtual screening of the G. lucidum compound library through the validation of the test set. Finally, 31 potential G. lucidum active constituents were screened and chosen to activate the FXRs. The ADMET results showed that ganoderic acid H and lucidenic acid J had less than 90% plasma protein binding rate and no hepatotoxicity, which could be used as FXR activators for developing clinical drugs for the treatment of liver fibrosis, either alone or in combination.
The invention provides a kind of healthy harmonized oil containing linoleic acid and linolenic acid at a ratio of 4:1 for pregnant women. The harmonized oil is composed of perillartine, oleum lini, sunflower oil, oleum camelliae and bean oil at an uncertain ratio. There is 50wt.% essential fatty acid, 40wt.% linoleic acid, 10wt.% linolenic acid in the harmonized oil. Linolenic acid (C18:3, Omega-3) which can grow to eicosapentaenoic acid (EPA, C20:5, Omega-3) under the affect of enzyme of human liver is added into the edible vegetable oil. EPA is considered to be the main substance capable of cleaning blood dirties in blood vessels and is called as street sweeper of blood vessels by medical experts. EPA can also grow to docosahexaenoic acid (DHA, C22:6, Omega- 3) which is the core substance for forming brain and amphiblestroid membrane occupying one quarter of the whole brain and is called as brain gold by nutritionist. Thus, the prescription has influential contribution in promoting infant intelligence, protecting eyesight, promoting brain formation and reinforcing remembrance.
FIELD: veterinary medicine. SUBSTANCE: method of treatment and prophylaxis involves administration of preparation into the damaged organ. Preparation has alum, resorcinol, sodium salicylate, sulfur, chrome sulfate, thioglycolic acid and glucose. Preparation is administrated by intrauterine and intracysternal routs at endometritis and mastitis, respectively. Components of the preparation show complex and versatile effects. EFFECT: enhanced effectiveness of treatment and prophylaxis. 1 ex
Seventy subjects will be enrolled and randomized to start either a low sodium diet (1200 mg/day) or high sodium diet (\>4200 mg/day) for two weeks. After completion of two weeks, subjects will be switched to the 'other' diet for two weeks after a one-week wash-out. During the screening visit, subject's daily sodium intake will be assessed using multiple methods and further dietary information will be collected to prepare customized low sodium meals. During low sodium diet period, subjects will be supplied with food and will be asked to keep food logs. At the end of two-week period, the study activities described below will be carried out including BOLD MRI imaging along with imaging techniques to assess renal oxygenation levels and perfusion. During high sodium diet period, subjects will be either supplemented with sodium chloride tablets or high sodium foods to achieve a daily sodium intake above 4200 mg/day. If subjects already consume over 4200 mg/day of sodium, no changes will be made to their diet and assessment of oxygenation (BOLD MRI) and perfusion will take place after two weeks.

At the end of high sodium diet, 18 subjects will have renal vein sampling performed (this will be equally divided between salt-sensitive and salt-insensitive subjects and per subject preference as all may not want to have renal vein sampling). Subjects will be classified into salt sensitive or insensitive at the end of low sodium diet period based on BP response for further data analyses.
Metoclopramide can cause tardive dyskinesia (TD), a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities. Movements may be choreoathetotic in appearance. The risk of developing TD and the likelihood that TD will become irreversible increases with duration of treatment and total cumulative dosage. Additionally, the risk of developing TD is increased among the elderly, especially elderly women [see Use in Specific Populations (8.5)], and in patients with diabetes mellitus. Due to the risk of developing TD, avoid treatment with Reglan for longer than 12 weeks and reduce the dosage in elderly patients [see Dosage and Administration (2.2, 2.3)].

Discontinue Reglan immediately in patients who develop signs and symptoms of TD. There is no known effective treatment for established cases of TD, although in some patients TD may remit, partially or completely, within several weeks to months after Reglan is withdrawn.

Reglan itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of TD is unknown. Reglan is contraindicated in patients with a history of TD [see Contraindications (4)]. Avoid Reglan in patients receiving other drugs that are likely to cause TD (e.g., antipsychotics).
Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
Stimulating cardiomyocyte proliferation in the adult heart has emerged as a promising strategy for cardiac regeneration following myocardial infarction (MI). The NRG1-ERBB4 signaling pathway has been implicated in the regulation of cardiomyocyte proliferation. However, the therapeutic potential of recombinant human NRG1 (rhNRG1) has been limited due to the low expression of ERBB4 in adult cardiomyocytes. Here, we investigated whether a fusion protein of rhNRG1 and an ERBB3 inhibitor (rhNRG1-HER3i) could enhance the affinity of NRG1 for ERBB4 and promote adult cardiomyocyte proliferation. In vitro and in vivo experiments were conducted using postnatal day 1 (P1), P7, and adult cardiomyocytes. Western blot analysis was performed to assess the expression and activity of ERBB4. Cardiomyocyte proliferation was evaluated using Ki67 and pH 3 immunostaining, while fibrosis was assessed using Masson staining. Our results indicate that rhNRG1-HER3i, but not rhNRG1, promoted P7 and adult cardiomyocyte proliferation. Furthermore, rhNRG1-HER3i improved cardiac function and reduced cardiac fibrosis in post-MI hearts. Administration of rhNRG1-HER3i inhibited ERBB3 phosphorylation while increasing ERBB4 phosphorylation in adult mouse hearts. Additionally, rhNRG1-HER3i enhanced angiogenesis following MI compared to rhNRG1. In conclusion, our findings suggest that rhNRG1-HER3i is a viable therapeutic approach for promoting adult cardiomyocyte proliferation and treating MI by enhancing NRG1-ERBB4 signaling pathway.
PURPOSE:To obtain the titled aqueous solution, by removing a protein denaturation agent from a dilute aqueous solution of human gamma-type interferon containing a protein denaturation agent, aging the solution in dissolved state, and concentrating the aged solution. CONSTITUTION:A dilute aqueous solution of human IFN-(R) (e.g. an aqueous solution of human IFN-(R) monomer obtained by the gel-filtration of crude human IFN-(R) in the presence of a reducing sulfur compound and a protein denaturation agent) containing a protein denaturation agent (e.g. guanidine salt, urea, thiocyanate, etc.) is subjected to the gel-filtration or ultrafiltration to remove the protein denaturation agent. The obtained dilute aqueous solution is let stand in liquid state at 0-40 deg.C for 0.5-7 days, preferably for 24-72hr to effect the aging of the solution. If necessary, the solution is subjected to e.g. aseptic filtration, etc. before aging. The aged solution is concentrated with an ultrafiltration membrane (having an MWCO of about 10,000) to obtain an aqueous solution of highly concentrated human IFN-gamma containing 0.2-1.5mg/ml of human IFN-(R). The product is suitable as an intermediate for the mass production of human IFN-gamma.
BACKGROUND: The immunomodulatory oligodeoxynucleotide (ODN) IMT504 might harbor antifibrotic properties within the liver.
METHODS: Fibrosis models were induced in mice through thioacetamide (TAA) administration and bile-duct ligation. Cre-loxP mice were utilized to identify GLAST + Wnt1 + bone marrow stromal progenitors (BMSPs) and to examine their contribution with cells in the liver. In vivo and in vitro assays; flow-cytometry, immunohistochemistry, and qPCR were conducted.
RESULTS: IMT504 demonstrated significant inhibition of liver fibrogenesis progression and reversal of established fibrosis. Early responses to IMT504 involved the suppression of profibrogenic and proinflammatory markers, coupled with an augmentation of hepatocyte proliferation. Additionally, this ODN stimulated the proliferation and mobilization of GLAST + Wnt1 + BMSPs, likely amplifying their contribution with endothelial- and hepatocytes-like cells. Moreover, IMT504 significantly modulated the expression levels of Wnt ligands and signaling pathway/target genes specifically within GLAST + Wnt1 + BMSPs, with minimal impact on other BMSPs. Intriguingly, both IMT504 and conditioned media from IMT504-pre-treated GLAST + Wnt1 + BMSPs shifted the phenotype of fibrotic macrophages, hepatic stellate cells, and hepatocytes, consistent with the potent antifibrotic effects observed.
CONCLUSION: In summary, our findings identify IMT504 as a promising candidate molecule with potent antifibrotic properties, operating through both direct and indirect mechanisms, including the activation of GLAST + Wnt1 + BMSPs.
A two-chain insulin analogue contains a modified A-chain polypeptide and a modified B-chain polypeptide. The A-chain polypeptide comprises one or more of: a His or Glu substitution at position A8, a Glu substitution at position A14; and a Gln or Arg substitution at positon A17. The B-chain polypeptide comprises one or more of: a deletion of the amino acids at position B1, B1-B2, B1-B3, B30 or a combination thereof; an Ala or Glu substitution at position B2; a Glu substitution at position B3. The analogue exhibits thermodynamic stability in a zinc-free solution, decreased self-association, maintains biological potency, and no increased mitogenicity. The analogue exhibits resistance to chemical degradation and physical degradation. A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.
Patients having haemodialysis treatment at least 3 times per week at a London Health Sciences Centre facility-Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
OBJECTIVES: To investigate the effectiveness and safety of combination of 655 nm low level laser helmet device with topical 2 % minoxidil solution at FPHL in Chinese population.
MATERIALS AND METHODS: Randomized, parallel, controlled, single-blind clinical trial was conducted. FPHL subjects were randomly allocated into 2 % minoxidil group and combination group. The 2 % minoxidil group received 1 ml topical 2 % minoxidil solution twice daily for 24 weeks. The combination group received 1 ml topical 2 % minoxidil solution twice daily together with 20 min 655 nm low-level laser helmet once every other day for 24 weeks. Hair parameters in two scalp areas including midscalp and vertex were evaluated at baseline, 12th week and 24th week.
RESULTS: In midscalp area, the combination group showed a lower increase in intermediate hair percentage than 2 % minoxidil group, which was statistically significant. Besides, the combination group had statistically significant increase than 2 % minoxidil group in mean hair diameter. Reported relative adverse events included slightly hair loss (27.8 %), desquamation (19.0 %), pruritus (15.2 %), seborrhea (2.5 %) and hypertrichosis (2.5 %).
CONCLUSION: In our trial, LLLT was demonstrated as a useful supplementary treatment for FPHL and the combination with 2 % minoxidil accomplished better improvement in intermediate hair enlargement and hair diameter of midscalp for FPHL.